Medicus Pharma Ltd (NASDAQ:MDCX – Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 3,559,666 shares, a growth of 290.7% from the February 26th total of 911,128 shares. Approximately 15.7% of the shares of the company are short sold. Based on an average trading volume of 20,131,918 shares, the days-to-cover ratio is presently 0.2 days. Based on an average trading volume of 20,131,918 shares, the days-to-cover ratio is presently 0.2 days. Approximately 15.7% of the shares of the company are short sold.
Analyst Ratings Changes
Several research analysts recently issued reports on MDCX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Medicus Pharma in a report on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and set a $27.00 price target on shares of Medicus Pharma in a research report on Thursday, March 19th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $23.50.
Get Our Latest Analysis on Medicus Pharma
Hedge Funds Weigh In On Medicus Pharma
Medicus Pharma Trading Down 2.2%
Shares of NASDAQ:MDCX opened at $0.49 on Wednesday. Medicus Pharma has a 12-month low of $0.37 and a 12-month high of $8.94. The business has a 50 day moving average of $1.03 and a two-hundred day moving average of $1.74. The company has a market capitalization of $12.49 million, a PE ratio of -0.23 and a beta of -1.58.
About Medicus Pharma
Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.
Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.
Read More
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
